Nobel Biocare appoints Frank Mengis as Head of Global Operations

(PresseBox) ( Kloten, )
Nobel Biocare announced today that Frank Mengis will be appointed Senior Vice President Global Operations and member of the Executive Committee, effective 1 July 2012. He will replace Ernst Zaengerle, who will be retiring.

Frank Mengis has extensive senior management experience in operations and manufacturing in the life sciences field including the dental industry. Most recently, he held senior management positions in Project Management and Development, Global Manufacturing, Operations and Quality Management at Straumann Institute. Prior to that, Frank Mengis was Head of Pharma Capital Investment Projects at Karl Steiner, Switzerland, after having held various management positions at F. Hoffmann-La Roche, Switzerland, in areas including galenical engineering and pharmaceutical manufacturing. Frank Mengis obtained a degree in Mechanical Engineering from the University of Karlsruhe, and completed the Advanced Management Program at Harvard Business School.

Nobel Biocare would like to thank Ernst Zaengerle for his commitment and contribution to Nobel Biocare, and wishes him all the best for his future.


This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to